Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.4%
- Check21 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.7%
- Check65 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check72 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the details of a clinical study for telisotuzumab vedotin in treating non-small cell lung cancer, including eligibility criteria and study phases. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference14%
- Check86 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.